ACLARUBICIN

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C42H53NO15
Molecular Weight	811.8679
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(CCC(=O)[C@H](C)O1)O[C@H]2[C@@H](O)C[C@]([H])(O[C@@H]3[C@H](C)O[C@]([H])(C[C@@H]3N(C)C)O[C@H]4C[C@](O)(CC)[C@H](C(=O)OC)C5=CC6=C(C(=O)C7=C(O)C=CC=C7C6=O)C(O)=C45)O[C@H]2C

InChI

InChIKey=USZYSDMBJDPRIF-SVEJIMAYSA-N

InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C42H53NO15
Molecular Weight	811.8679
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	13 / 13
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.toku-e.com/product/aclarubicin_hydrochloride/
Curator's Comment: description was created based on several sources, including: http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8

Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase II 66 Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23533247	Inhibitor 8228

Conditions

Condition	Modality	Highest Phase	Product
Small-cell lung cancer 41 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1321008	Primary	Phase II 1144	Unknown Approved Use Unknown
Thyroid cancer 16 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3181249	Primary	Phase II 1144	Unknown Approved Use Unknown
Lymphoma 60 Sources: http://www.ncbi.nlm.nih.gov/pubmed/3867405	Primary	Phase II 1144	Unknown Approved Use Unknown
Gastrointestinal adenocarcinoma 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2206579	Primary	Phase I 424	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Inhibition by doxorubicin of human immuno-deficiency virus (HIV) infection and replication in vitro.	1987 Mar	2437093
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.	1993 Dec	8109920
Enhancement of chemosensitivity toward anticancer drugs by high expression of caspase-1 in NIH 3T3 cells.	1998 Jan	9491796
Oxidative stress involvement in chemically induced differentiation of K562 cells.	2000 Jan 1	10656287
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.	2000 May	10815900
Expression of glutathione S-transferase P1-1 in differentiating K562: role of GATA-1.	2003 Nov 28	14623254
Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.	2005 Dec	16215684
Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening.	2009 Mar 24	19255438
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003
Discovery, synthesis, and biological evaluation of novel SMN protein modulators.	2011 Sep 22	21819082

Patents

Sample Use Guides

In Vivo Use Guide

25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week

Route of Administration: Intravenous

In Vitro Use Guide

aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 22:48:08 UTC 2023` Edited by `admin` on `Wed Jul 05 22:48:08 UTC 2023`
Record UNII	74KXF8I502
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACLARUBICIN

Official Name

English

ACLARUBICIN [JAN]

Common Name

English

ACLACINOMYCIN A

Common Name

English

Aclarubicin [WHO-DD]

Common Name

English

ACLACINOMYCIN A [MI]

Common Name

English

ACLARUBICIN [USAN]

Common Name

English

ACLARUBICIN [MART.]

Common Name

English

NSC-208734

Code

English

aclarubicin [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QL01DB04